Company intelligence / Profile preview
Phoenix Molecular Designs
Vancouver, British Columbia, Canadaphoenixmd.ca ↗
- Ownership
- Private
- Employees
- ~19
- Development stage
- Other
01
Overview
Phoenix Molecular Designs has advanced its lead compound, PMD‑026—a first-in-class small molecule inhibitor targeting the RSK pathway—into Phase 2 clinical trials for breast cancer. The company’s approach addresses resistance to current therapies and aims to improve outcomes in difficult-to-treat cancers such as TNBC. No published late-stage or commercial results yet.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule kinase inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Phoenix Molecular Designs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phoenix Molecular Designs.